In the latest quarter, 10 analysts provided ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE), showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Analysts have set 12-month price targets for Ultragenyx Pharmaceutical, revealing an average target of $89.7, a high estimate of $116.00, and a low estimate of $45.00. Marking an increase of 1.59%, the current average surpasses the previous average price target of $88.30.

Diving into Analyst Ratings: An In-Depth Exploration

A comprehensive examination of how financial experts perceive Ultragenyx Pharmaceutical is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ultragenyx Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Ultragenyx Pharmaceutical analyst ratings.

Delving into Ultragenyx Pharmaceutical's Background

Ultragenyx Pharmaceutical's Financial Performance

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Ultragenyx Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 35.75%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Ultragenyx Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of -89.51%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -45.96%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -9.0%, the company may face hurdles in achieving optimal financial performance.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.